Brasil
| Preprint
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study
Registro en:
HITCHINGS, Matt D. T. et.al. Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study. MedRxiv preprint, p. 1-23, 2021.
10.1101/2021.12.23.21268335
Autor
Hitchings, Matt D. T.
Ranzani, Otavio T.
Lind, Margaret L.
Dorion, Murilo
D’Agostini, Tatiana Lang
Paula, Regiane Cardoso de
Paula, Olivia Ferreira Pereira de
Villela, Edlaine Faria de Moura
Torres, Mario Sergio Scaramuzzini
Oliveira, Silvano Barbosa de
Schulz, Wade
Almiron, Maria
Said, Rodrigo
Oliveira, Roberto Dias de
Silva, Patricia Vieira da
Araújo, Wildo Navegantes de
Gorinchteyn, Jean Carlo
Dean, Natalie E.
Andrews, Jason R.
Cummings, Derek A. T.
Ko, Albert I.
Croda, Julio
Resumen
Instituto Nacional de Alergia e Doenças Infecciosas para N.E.D. Objective To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil. Design Test negative case-control study. Setting Community testing for covid-19 in São Paulo state, Brazil. Participants Adults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021. Main outcome measures RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection. Results From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 testnegative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days. Conclusions In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.